Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: Results from a multi-center study in German speaking countries

European Journal of Neurology

Volumn 17, Issue 1, 2010, Pages 31-37

  Putzki, N ^a,b   Yaldizli, O ^b   Maurer M ^c   Cursiefen, S ^c   Kuckert, S ^d   Klawe, C ^e   Maschke, M ^e   Tettenborn, B ^b   Limmroth, V ^c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e Barmherzige Brueder Hospital   (Germany)

Author keywords

Disease modifying therapy; Multiple sclerosis; Natalizumab; Treatment failure

Indexed keywords

BETA INTERFERON; GADOLINIUM; GLATIRAMER; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; RITUXIMAB;

ADULT; ARTICLE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK REDUCTION; SWITZERLAND; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM; CONTRAST MEDIA; DISABILITY EVALUATION; DRUG RESISTANCE; FEMALE; GADOLINIUM; GERMANY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDES; RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; YOUNG ADULT;

EID: 73449107729     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02728.x     Document Type: Article

References (20)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 354 : 899 910.
2. Yednock TA, Cannon C, Fritz L, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992 356 : 63 66.
3. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006 354 : 924 933.
4. European-Medicine-Agency (2006) http://www.emea.europa.eu/humandocs/PDFs/ EPAR/tysabri/H-603-en6.pdf.
5. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006 354 : 911 923.
6. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 13 : 227 231.
7. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 50 : 121 127.
8. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004 56 : 548 555.
9. Sorensen PS, Tscherning T, Mathiesen HK, et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006 67 : 1681 1683.
10. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007 6 : 431 441.
11. Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2006 13 : 471 474.
12. Carra A, Onaha P, Luetic B, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 2008 15 : 386 393.
13. Limmroth V, Putzki N. High-dose, frequently administered interferon-beta. J Neurol Sci 2005 15 : 95 96.
14. Confavreux C, Vukusic S. Non-specific immunosuppressants in the treatment of multiple sclerosis. Clin Neurol Neurosurg 2004 106 : 263 269.
15. Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology 2004 63 (Suppl. 6 S8 S14.
16. Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology 2007 68 : 1524 1528.
17. Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V 2008) Natalizumab is effective as second line therapy in the treatment of relapsing remitting MS. Eur J Neurol 2009 16 : 424 426
18. Oturai AB, Koch-Henriksen N, Petersen T, et al. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009 16 : 420 423.
19. Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009 doi : (Epub ahead of print).
20. Gold R, Jawad A, Miller DH, et al. Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol 2007 187 : 156 158.